Back

Mutations Leading to Ceftolozane/Tazobactam and Imipenem/Cilastatin/Relebactam Resistance During in vivo exposure to Ceftazidime/Avibactam in Pseudomonas aeruginosa

Rapsinski, G. J.; Rokes, A.; Van Tyne, D.; Cooper, V. S.

2024-09-10 microbiology
10.1101/2024.09.10.612322 bioRxiv
Show abstract

Identifying resistance mechanisms to novel antimicrobials informs treatment and antimicrobial development, but frequently identifies multiple candidate resistance mutations without resolving the driver mutation. Using whole genome sequencing of longitudinal Pseudomonas aeruginosa that developed imipenem/cilastatin/relebactam and ceftolozane/tazobactam resistance during ceftazidime/avibactam treatment, we determined mutations resulting in cross-resistance. Penicillin-binding protein ftsI, transcriptional repressor bepR, and virulence regulator pvdS were found in resistant isolates. We conclude that peptidoglycan synthesis gene mutations can alter the efficacy of multiple antimicrobials.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.